Product in development

ESiNAR-X® platform

Personalized antisense therapeutic modalities.

  • Currently tested for oncological diseases
  • Custom-made oligonucleotides
  • Pre-clinical validation
  • 99% selectivity for cancer cells
  • 99% efficacy in therapeutic function
  • Universal applicability
Stage of Development

70%

 
 
Be updated

Get a free notification

error: Content is protected !!